Поиск Поиск структуры
wx_img
Inquiry Form
  1. Home
  2. BTX-A51

BTX-A51

Edgewood Oncology announced that the first two patients with metastatic breast cancer were treated with BTX-A51, a multi-specific kinase inhibitor of casein kinase 1 alpha (CK1α) and cyclin-dependent kinases 7 and 9 (CDK7 and CDK9), that synergistically targets master regulators of cancer. BTX-A51 is being evaluated in a Phase 2a study for the treatment of estrogen receptor positive / human epidermal growth factor receptor 2 negative (ER+/HER2-) metastatic breast cancer with and without GATA binding protein 3 (GATA3) mutations.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.

α-Cyclopropyl-1-methyl-1H-pyrazole-5-methanol
α-Cyclopropyl-1-methyl-1H-pyrazole-5-methanol
CM1077693
1339787-34-6
5-(cyclopropylmethyl)-1-methyl-1H-pyrazole
5-(cyclopropylmethyl)-1-methyl-1H-pyrazole
CM773831
2079069-44-4
4-bromo-5-(cyclopropylmethyl)-1-methyl-1H-pyrazole
4-bromo-5-(cyclopropylmethyl)-1-methyl-1H-pyrazole
CM423884
2079069-45-5
5-(cyclopropylmethyl)-1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
5-(cyclopropylmethyl)-1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
CM430407
2079069-46-6
2,5-Dichloro-4-(5-(cyclopropylmethyl)-1-methyl-1H-pyrazol-4-yl)pyrimidine
2,5-Dichloro-4-(5-(cyclopropylmethyl)-1-methyl-1H-pyrazol-4-yl)pyrimidine
CM1077692
2079069-47-7